Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Cytomedix

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effectiveness of Aurix Therapy in Venous Leg Ulcers

Phase 4

Withdrawn

Conditions: Venous Leg Ulcers

Interventions: Device: Aurix

First Posted Date: 2016-10-21

Last Posted Date: 2016-10-21

Lead Sponsor: Cytomedix

Registration Number: NCT02940587

Locations: 🇺🇸
St. Luke's Intermountain Research, Boise, Idaho, United States

A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers

Phase 4

Withdrawn

Conditions: Impaired Wound Healing

Interventions: Other: Usual and Customary Care (UCC)
Device: AutoloGel

First Posted Date: 2014-09-25

Last Posted Date: 2016-10-21

Lead Sponsor: Cytomedix

Registration Number: NCT02248077

AutoloGel Therapy to Usual and Customary Care in Pressure Ulcers

Not Applicable

Terminated

Conditions: Pressure Ulcer

Interventions: Device: AutoloGel

First Posted Date: 2013-03-27

Last Posted Date: 2016-10-21

Lead Sponsor: Cytomedix

Target Recruit Count: 2

Registration Number: NCT01819142

Locations: 🇺🇸
Singing River, Pascagaula, Mississippi, United States

A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers

Not Applicable

Terminated

Conditions: Venous Leg Ulcer

Interventions: Device: AutoloGel

First Posted Date: 2013-03-25

Last Posted Date: 2016-10-21

Lead Sponsor: Cytomedix

Target Recruit Count: 2

Registration Number: NCT01817543

Locations: 🇺🇸
HyperBarxs at Northside Forsyth, Cumming, Georgia, United States

Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner gd 1 and 2 Diabetic Foot Ulcers.

Not Applicable

Terminated

Conditions: Diabetic Foot Ulcer

Interventions: Device: AutoloGel
Other: Usual and Customary Care

First Posted Date: 2013-03-22

Last Posted Date: 2016-10-21

Lead Sponsor: Cytomedix

Target Recruit Count: 4

Registration Number: NCT01816672

Locations: 🇺🇸
Forest General Hospital, Hattiesburg, Mississippi, United States

Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers

Not Applicable

Terminated

Conditions: Diabetic Foot Ulcers

Interventions: Device: AutoloGel

First Posted Date: 2013-03-22

Last Posted Date: 2016-10-21

Lead Sponsor: Cytomedix

Target Recruit Count: 3

Registration Number: NCT01816633

Locations: 🇺🇸
HyperBarxs at Northside Forsyth, Cumming, Georgia, United States

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Phase 2

Conditions: Stroke in Middle Cerebral Artery (MCA)
Ischemic Stroke
Stroke

Interventions: Biological: ALD-401
Procedure: Sham Procedure

First Posted Date: 2011-01-10

Last Posted Date: 2014-01-16

Lead Sponsor: Aldagen

Target Recruit Count: 100

Registration Number: NCT01273337

Locations: 🇺🇸
Los Angeles Brain and Spine Institute, Los Angeles, California, United States
🇺🇸
University of Miami Hospital, Miami, Florida, United States
🇺🇸
Minneapolis Heart Institute, Minneapolis, Minnesota, United States

and more 6 locations

The AutoloGel™ Post-Market Surveillance (TAPS) Program

Not Applicable

Terminated

Conditions: Wounds
Leg Ulcers
Diabetic Foot Ulcers
Pressure Ulcers

Interventions: Device: AutoloGel System

First Posted Date: 2008-09-30

Last Posted Date: 2014-02-26

Lead Sponsor: Cytomedix

Target Recruit Count: 131

Registration Number: NCT00762138

Locations: 🇺🇸
Aiyan Diabetes Center, Augusta, Georgia, United States
🇺🇸
Providence Wound Institute, El Paso, Texas, United States

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

Phase 3

Terminated

Conditions: Inherited Metabolic Diseases
Inborn Errors of Metabolism
Mucopolysaccharidosis
Lysosomal Storage Disorders
Peroxisomal Storage Diseases

Interventions: Biological: ALD-101

First Posted Date: 2008-04-08

Last Posted Date: 2014-07-08

Lead Sponsor: Aldagen

Target Recruit Count: 40

Registration Number: NCT00654433

Locations: 🇺🇸
Mattel Children's Hospital at UCLA, Los Angeles, California, United States
🇺🇸
Mt. Sinai Medical Center, New York, New York, United States
🇺🇸
Duke University, Durham, North Carolina, United States

ALD-301 for Critical Limb Ischemia, Randomized Trial

Phase 1

Completed

Conditions: Critical Limb Ischemia
Peripheral Arterial Disease
Peripheral Vascular Disease

Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells

First Posted Date: 2006-10-26

Last Posted Date: 2009-05-14

Lead Sponsor: Aldagen

Target Recruit Count: 20

Registration Number: NCT00392509

Locations: 🇺🇸
Cardiology PC, Birmingham, Alabama, United States
🇺🇸
Saint Joseph's Research Institute, Atlanta, Georgia, United States
🇺🇸
University of Indiana at Indianapolis, Indianapolis, Indiana, United States

and more 2 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy